Susanne Beck

Susanne Beck

Auto-generated profile, based on publicly available information

Susanne Beck

Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2023 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FSFabian Stögbauer
Fabian Stögbauer
SBSusanne Beck
Susanne Beck
IOIordanis Ourailidis
Iordanis Ourailidis
JHJochen Hess
Jochen Hess
CPChristopher Poremba
Christopher Poremba
JBJan Budczies
Jan Budczies
Background: The prognostic significance of tumour budding (TB) and minimal cell nest size (MCNS) was shown in human papillomavirus (HPV)-negative head and neck squamous cell carcinomas (HNSCC). However, the optimisation of cutpoints, the prognostic impact in HPV-positive HNSCC, and the comparison with other histopathological grading systems are insufficiently investigated. Methods: TB and MCNS were analysed digitally in 1 and 10 high-power fields (HPF) of 331 HPV-positive and HPV-negative cases from TCGA. Optimising the cutpoints a new cellular dissociation grading (CDG) system was defined and compared to the WHO grading and the Brandwein–Gensler (BG) risk model. Results: The two-tiered CDG system based solely on TB yielded optimal prognostic stratification with shortened overall survival for CDG-high cases. Optimal cut-offs were two buds (1 HPF) and six buds (10 HPF), respectively. Analysing MCNS did not add prognostic significance to quantifying TB. CDG was a significant prognostic marker in HPV-negative and HPV-positive tumours and prognostically superior to the WHO and BG systems. High CDG was associated with clinically occult lymph-node metastases. Conclusions: The most comprehensive study of TB in HNSCC so far confirmed its prognostic impact in HPV-negative tumours and for the first time in HPV-positive tumours. Further studies are warranted to evaluate its applicability for therapy guidance in HNSCC.

14 April 2023 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
EREva Romanovsky
Eva Romanovsky
KKKlaus Kluck
Klaus Kluck
IOIordanis Ourailidis
Iordanis Ourailidis
MMMichael Menzel
Michael Menzel
SBSusanne Beck
Susanne Beck
JBJan Budczies
Jan Budczies
TP53 is the most frequently mutated gene in human cancer. While no TP53-targeting drugs have been approved in the USA or Europe so far, preclinical and clinical studies are underway to investigate targeting of specific or all TP53 mutations, for example, by restoration of the functionality of mutated TP53 (TP53mut) or protecting wildtype TP53 (TP53wt) from negative regulation. We performed a comprehensive mRNA expression analysis in 24 cancer types of TCGA to extract (i) a consensus expression signature shared across TP53 mutation types and cancer types, (ii) differential gene expression patterns between tumors harboring different TP53 mutation types such as loss of function, gain of function or dominant-negative mutations, and (iii) cancer-type-specific patterns of gene expression and immune infiltration. Analysis of mutational hotspots revealed both similarities across cancer types and cancer type-specific hotspots. Underlying ubiquitous and cancer type-specific mutational processes with the associated mutational signatures contributed to explaining this observation. Virtually no genes were differentially expressed between tumors harboring different TP53 mutation types, while hundreds of genes were over- and underexpressed in TP53mut compared to TP53wt tumors. A consensus list included 178 genes that were overexpressed and 32 genes that were underexpressed in the TP53mut tumors of at least 16 of the investigated 24 cancer types. In an association analysis of immune infiltration with TP53 mutations in 32 cancer subtypes, decreased immune infiltration was observed in six subtypes, increased infiltration in two subtypes, a mixed pattern of decreased and increased immune cell populations in four subtypes, while immune infiltration was not associated with TP53 status in 20 subtypes. The analysis of a large cohort of human tumors complements results from experimental studies and supports the view that TP53 mutations should be further evaluated as predictive markers for immunotherapy and targeted therapies.

13 March 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
IOIordanis Ourailidis
Iordanis Ourailidis
FSFabian Stögbauer
Fabian Stögbauer
YZYuxiang Zhou
Yuxiang Zhou
SBSusanne Beck
Susanne Beck
EREva Romanovsky
Eva Romanovsky
JBJan Budczies
Jan Budczies
Tumor budding (TB) is a prognostic biomarker in HPV-negative and HPV-positive head and neck squamous cell carcinoma (HNSCC). Analyzing TCGA and CPTAC mutation, RNA, and RPPA data and performing proteomics and IHC in two independent in-house cohorts, we uncovered molecular correlates of TB in an unprecedentedly comprehensive manner. NSD1 mutations were associated with lower TB in HPV-negative HNSCC. Comparing budding and nonbudding tumors, 66 miRNAs, including the miRNA-200 family, were differentially expressed in HPV-negative HNSCC. 3,052 (HPV-negative HNSCC) and 360 (HPV-positive HNSCC) RNAs were differentially expressed. EMT, myogenesis, and other cancer hallmarks were enriched in the overexpressed RNAs. In HPV-negative HNSCC, 88 proteins were differentially expressed, significantly overlapping with the differentially expressed RNAs. CAV1 and MMP14 protein expression investigated by IHC increased gradually from nonbudding tumors to the bulk of budding tumors and tumor buds. The molecular insights gained support new approaches to therapy development and guidance for HNSCC.

12 December 2024 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
MBMarkus Ball
Markus Ball
EREva Romanovsky
Eva Romanovsky
FSFabian Schnecko
Fabian Schnecko
MKMartina Kirchner
Martina Kirchner
ONOlaf Neumann
Olaf Neumann
DKDaniel Kazdal
Daniel Kazdal
The adoption of comprehensive genomic profiling in oncology has rapidly increased the demand for standardized tumor sample processing in diagnostic laboratories. Automation of DNA and RNA library preparation workflows offers the possibility to scale-up and standardize sample processing. We report on the clinical implementation of the automated TruSight Oncology 500 High-Throughput library preparation workflow from formalin-fixed paraffin-embedded tumor samples using the Biomek i7 hybrid Workstation. Using the same input amount, the automated workflow was validated against manual library preparation. Quality control metrics (total and mapped reads, median insert size, median exon coverage) and the detection of tumor mutational burden, a complex biomarker, were concordant between manual and automated workflows. The automated workflow was implemented on a total of 2,997 pan-cancer clinical samples to detect genomic variants and complex biomarkers. Workflow automation resulted in a 4-fold reduction in hands-on time and 1.7-fold reduction in total runtime compared to manual library preparation (6 hours vs 23 hours; 24 hours vs 42.5 hours, respectively) for a 48 DNA + 48 RNA sample batch. The automated workflow required one technician vs three technicians to manually prepare the same number of libraries. This study shows, that implementation of the automated TruSight Oncology 500 High-Throughput workflow significantly reduced hands-on time and processing time per sample compared to manual library preparation.

5 September 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
DMDaniela Simone Maichl
Daniela Simone Maichl
JKJulius Arthur Kirner
Julius Arthur Kirner
SBSusanne Beck
Susanne Beck
WCWen-Hui Cheng
Wen-Hui Cheng
MKMelanie Krug
Melanie Krug
FJFranziska Jundt
Franziska Jundt

7 April 2026 in British Journal of Cancer
Verified
Journal Article
Open access
CAChristian Altbürger
Christian Altbürger
MMMichael Menzel
Michael Menzel
SBSusanne Beck
Susanne Beck
KLKatja Lorenz
Katja Lorenz
MBMarie-Luise Brygider
Marie-Luise Brygider
Albrecht  StenzingerAlbrecht Stenzinger
Albrecht Stenzinger
Background: Molecular characterisation of solid tumours contributes to a precise diagnosis and can uncover a range of drug targets and biomarkers, improving patient management. Whole genome sequencing (WGS) combined with whole transcriptome sequencing (WTS) is the most comprehensive approach in molecular cancer diagnostics and is therefore becoming increasingly integrated in clinical care. A critical challenge in implementing WGS/WTS as a clinical-grade test is its high cost compared to targeted sequencing approaches, prohibiting wider use and access. Methods: To dissect this limitation, we performed a micro-costing analysis of an established WGS/WTS workflow based on short-read sequencing technology. We categorised the costs as follows: consumables, equipment and maintenance, personnel, and data processing/storage. We considered various scenarios, including sample volumes, personnel and equipment redundancy, inflation and mean coverage. Results: We have developed a multidimensional costing model that identified consumable costs, particularly flow cells, as the main cost drivers. While personnel and equipment costs decreased with larger case volumes processed (scaling effects), consumable and data processing/storage costs did not change significantly. Conclusions: Thus, falling prices of consumables would facilitate the broad implementation of WGS/WTS as a clinical-grade test.